NCT00311467 is a Phase 3 clinical trial of Capecitabine, Interferon, Interleukin in Renal Cell Cancer, sponsored by Central European Cooperative Oncology Group.

Who is sponsoring NCT00311467?

NCT00311467 is sponsored by Central European Cooperative Oncology Group.

What drugs are being tested in NCT00311467?

Interventions in NCT00311467: Capecitabine, Interferon, Interleukin.

What condition does NCT00311467 study?

NCT00311467 studies Renal Cell Cancer.

Is NCT00311467 still recruiting?

NCT00311467 is currently terminated. Last updated 15 May 2012.

Last reviewed 2012-05-15 · How we verify

NCT00311467

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma: a Prospective, Randomized, Multi-center phaseIII-Trial

Terminated Phase 3 Last updated 15 May 2012

What this trial tests

Phase 3 trial testing Capecitabine, Interferon, Interleukin in Renal Cell Cancer in 172 participants. Terminated before completion.

Timeline

1 March 2004

Primary endpoint
1 May 2007

1 May 2007

Quick facts

Lead sponsor	Central European Cooperative Oncology Group
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	172
Start date	1 March 2004
Primary completion	1 May 2007
Estimated completion	1 May 2007
Sites	1 location across Austria

Drugs / interventions tested

Capecitabine, Interferon, Interleukin — full drug profile →

Conditions studied

Renal Cell Cancer — all drugs for Renal Cell Cancer →

Sponsor

Central European Cooperative Oncology Group

Who can join

Adults 19 to 75, any sex, with Renal Cell Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The primary study objective is to investigate whether the addition of capecitabine to interferon-alpha-interleukin-2 based immunotherapy may improve progression free survival when compared to immunotherapy alone.

Sponsor's own description

Multi-center, prospective randomised phase III study evaluating capecitabine in combination with standard-immunotherapy versus standard-immunotherapy alone as first-line therapy in patients with metastatic renal cell carcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy.
Wu HL, Gong Y, Ji P, Xie YF, et al · · 2022 · cited 123× · PMID 35477416 · DOI 10.1186/s13045-022-01263-x

Verify or expand the search:

Other recruiting trials for Renal Cell Cancer

Currently open trials in the same condition.

NCT07294859 — Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy · recruiting
NCT06903312 — Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations. · Phase 4 · recruiting
NCT07020169 — Using 3D Kidney Model Based on Artificial Intelligence to Assist Partial Nephrectomy: A Prospective Validation Study · NA · recruiting
NCT06714916 — Optimising Renal Tumour Management Through Artificial Intelligence Modules · recruiting
NCT06751498 — The Value of a Convolutional Neural Network-Based Renal Artery Perfusion Model in Predicting Renal Function After Partia · recruiting

Other Central European Cooperative Oncology Group trials

Trials by the same sponsor.

NCT01918761 — Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00311467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central European Cooperative Oncology Group
Last refreshed: 15 May 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00311467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing